DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Aurobindo Pharma Limited — Analyst/Investor Meet Para A-XBRL

NSE 50 min ago·26 Oct 2026, 7:03 am

Aurobindo Pharma

Aurobindo Pharma has informed stock exchanges about an upcoming meeting with analysts and institutional investors. This communication is a routine regulatory filing that signals the company is preparing to engage with the investment community. Such meetings often serve as a platform for management to discuss recent performance, strategic initiatives, and future outlooks with a focus on long-term value creation.

For investors, this update is a positive signal of transparency and active engagement. It provides an opportunity to gauge management's tone on key business segments and upcoming catalysts. While the specific agenda is not disclosed, it typically offers insights into the company's direction, which can be valuable for retail investors monitoring the pharma sector.